Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on July 14, 2026. The filing primarily addresses a significant regulatory milestone regarding the Company's lead product candidate, REVTORPYK (gedatolisib).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on regulatory events rather than financial performance.
Material Changes and Events
- FDA Approval: The U.S. Food and Drug Administration (FDA) approved REVTORPYK (gedatolisib) for the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
- Commercial Launch: The Company anticipates the commercial launch of REVTORPYK in late Q3 2026.
- Regulatory Pipeline: The Company plans to submit a supplemental New Drug Application (sNDA) in Q3 2026 for REVTORPYK to treat HR+/HER2-, PIK3CA mutated, locally advanced or metastatic breast cancer, based on results from the mutant cohort of the Phase 3 VIKTORIA-1 trial.
Outlook, Risks, and Management Commentary
Management indicated plans to host a live webcast and conference call on July 14, 2026, to discuss the FDA approval. The filing includes extensive forward-looking statements regarding the potential therapeutic benefits of gedatolisib, the timing of clinical trials, market opportunity, and commercialization plans.
Risks and Uncertainties: The Company cautioned that forward-looking statements are subject to risks, including:
- Changes in clinical trial data following comprehensive review.
- Unforeseen delays in clinical trials or FDA review of the sNDA.
- Ability to obtain and maintain regulatory approvals.
- Market acceptance of gedatolisib and competition from other therapies.
- Ability to access capital upon favorable terms.
Investor Verification Checklist
- Verify the specific indications and patient population approved by the FDA for REVTORPYK as detailed in the press release (Exhibit 99.1).
- Confirm the timeline for the commercial launch in late Q3 2026 and associated commercialization strategy.
- Monitor the submission and FDA review status of the sNDA for the PIK3CA mutated indication expected in Q3 2026.
- Review the Company's most recent Form 10-K for detailed financial position, cash runway, and liquidity status, as this 8-K does not contain financial statements.
- Assess the competitive landscape for HR+/HER2- breast cancer treatments to evaluate market acceptance risks.